Torthaí cuardaigh - Roger von Moos

Beachtaigh na torthaí
  1. 1
    Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain

    Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain de réir Roger von Moos, Luís Costa, Carla Ripamonti, Daniela Niepel, Daniele Santini

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma

    Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma de réir Reinhard Dummer, Merlin Guggenheim, AW Arnold, Ralph P. Braun, Roger von Moos

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study

    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study de réir Ignace Vergote, Roger von Moos, Luís Manso, Els Van Nieuwenhuysen, Nicole Concin, Cristiana Sessa

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

    Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody de réir Roger von Moos, Luís Costa, Eva González‐Suárez, Evangelos Terpos, Daniela Niepel, Jean‐Jacques Body

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

    Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer de réir G. Fürstenberger, Roger von Moos, Rudolf Lucas, Beat Thürlimann, H-J Senn, Jürg Hamacher, E-M Boneberg

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland

    A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland de réir Tämer El Saadany, Judith E. Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, Roger von Moos

    Foilsithe / Cruthaithe 2025
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment

    Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment de réir A Glaus, Ch. Boehme, Beat Thürlimann, Thomas Ruhstaller, S.‐F. Hsu Schmitz, R. Morant, H.-J. Senn, Roger von Moos

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing

    A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing de réir Klazien Matter‐Walstra, Matthias Schwenkglenks, Stefan Aebi, Konstantin J. Dedes, Joachim Diebold, Mario Pietrini, Dirk Klingbiel, Roger von Moos, Oliver Gautschi

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

    Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours de réir Gianluca Del Conte, Cristiana Sessa, Roger von Moos, Lucia Viganò, Tiziana Digena, Alberta Locatelli, Elisa Gallerani, Angelica Fasolo, Anna Tessari, Richard Cathomas, Luca Gianni

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

    Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study de réir Florian Strasser, Thomas A. Lutz, Micha T. Maeder, B. Thuerlimann, Doug Bueche, M. Tschöp, K. Kaufmann, Birgitte Holst, Michael Brändle, Roger von Moos, Ruth Demmer, T. Cerny

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study

    Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study de réir Carlos Gomez‐Roca, Jean‐Pierre Delord, Caroline Robert, Manuel Hidalgo, Roger von Moos, Ana Arance, Elena Élez, Daniela Michel, Abdelkader Seroutou, Tim Demuth, Josep Tabernero

    Foilsithe / Cruthaithe 2014
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer

    Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer de réir Dieter Koeberle, Roger Burkhard, Roger von Moos, Sun Young Rha, Viviane Hess, F. Heitzmann, Thomas Ruhstaller, L. Terraciano, J. Neuweiler, G. Bieri, C Rust, M. Toepfer

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma

    The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma de réir Reinhard Dummer, Marco Siano, Robert E. Hunger, Nicole Lindenblatt, Ralph P. Braun, Olivier Michielin, Daniela Mihic‐Probst, Roger von Moos, Yousef Najafi, Matthias Gückenberger, Andreas Arnold

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma

    Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma de réir Ying Waeckerle‐Men, Edith Uetz‐von Allmen, M. Fopp, Roger von Moos, Christel Böhme, Hans‐Peter Schmid, Daniel Ackermann, Thomas Cerny, Burkhard Ludewig, Marcus Groettrup, Silke Gillessen

    Foilsithe / Cruthaithe 2006
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-randomized phase III study (SAKK 95/06)

    The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-ran... de réir Florian Strasser, David Blum, Roger von Moos, Richard Cathomas, Karin Ribi, Stefan Aebi, Daniel Betticher, Stefanie Hayoz, Dirk Klingbiel, Peter Brauchli, Michael Haefner, Silvia Mauri, S. Kaasa, Dieter Koeberle

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

    Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tu... de réir David H. Henry, Saroj Vadhan‐Raj, Vera Hirsh, Roger von Moos, Vânia Hungria, Luís Costa, Penella J. Woll, Giorgio V. Scagliotti, Geoffrey Smith, Amy Feng, Susie Jun, Roger Dansey, Howard Yeh

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid

    Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid de réir Saroj Vadhan‐Raj, Roger von Moos, Lesley Fallowfield, Donald L. Patrick, François Goldwasser, Charles S. Cleeland, David H. Henry, Silvia Novello, Vânia Hungria, Yi Qian, A. Feng, Hong‐Zen Yeh, Karen Chung

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)

    Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAK... de réir Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, Helmut Kranzbuehler, Roger von Moos, Peter Moosmann, Michael Montemurro, Paul M. Schneider, Daniel Rauch, Oliver Gautschi, Walter Mingrone, Lucas Widmer, Roman Inauen, Peter Brauchli, Viviane Hess

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)

    Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02) de réir Thomas Ruhstaller, L. Widmer, Jan C. Schuller, A. Roth, Viviane Hess, Walter Mingrone, Roger von Moos, Markus Borner, Bernhard C. Pestalozzi, Sabine Balmer-Majno, Dieter Köberle, L. Terraciano, Armin Schnider, Stephan Bodis, Răzvan Popescu

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)

    First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07) de réir Roger von Moos, Burkhardt Seifert, Mathew Simcock, Simone M. Goldinger, Silke Gillessen, Adrian F. Ochsenbein, Olivier Michielin, Richard Cathomas, Marc Schläppi, Holger Moch, Peter Schraml, D. Mjhic-Probst, Christoph Mamot, Nicola Schönewolf, Reinhard Dummer

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: